Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory diseases, including kidney and respiratory diseases, with a focus on new kidney therapies in areas with unmet medical needs. The Company pursues new product concepts and applies scientific knowledge to the discovery of products from early-stage development through to commercialisation. Its products are DMX-652 for Acute Kidney Injury and DMX-200 for Focal Segmental Glomerulosclerosis (FSGS). The Company operates in one segment, being investment in research and development of biopharmaceutical drugs.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
15
Stocks News & Analysis
stocks
Chart of the Week: ASX retail offers pockets of value in softening conditions
Why slowing consumer spending could create opportunities in overlooked retail stocks.
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,794.40 | 174.80 | -1.95% |
| CAC 40 | 7,919.53 | 44.98 | -0.56% |
| DAX 40 | 25,085.39 | 113.80 | -0.45% |
| Dow JONES (US) | 50,906.05 | 443.87 | -0.86% |
| FTSE 100 | 10,492.52 | 113.48 | -1.07% |
| HKSE | 24,613.27 | 89.70 | 0.37% |
| NASDAQ | 26,861.06 | 63.52 | 0.24% |
| Nikkei 225 | 68,956.72 | 2,203.00 | 3.30% |
| NZX 50 Index | 13,810.51 | 23.88 | -0.17% |
| S&P 500 | 7,651.54 | 19.30 | -0.25% |
| S&P/ASX 200 | 8,614.40 | 174.90 | -1.99% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |